J&J nabs accelerated FDA OK for one of their top late-stage drugs
Score one new potential blockbuster OK for J&J.
The FDA offered a quick stamp of approval for their solid tumor drug erdafitinib Friday afternoon, allowing the pharma giant to put a checkmark by one of their top pipeline projects. Execs highlighted this drug close to 2 years ago as one of the top 11 therapies they were steering through late-stage trials. And it’s a key part of an R&D plan aimed at reviving sales growth.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.